Crispr Therapeutics shares tumble after significant earnings miss
In a stark reflection of investor sentiment, Teladoc Inc (NYSE:TDOC)’s stock has tumbled to $6.64, near its 52-week low of $6.61. The telehealth company, with a market capitalization of $1.16 billion and annual revenue of $2.57 billion, has seen a significant reversal in fortune over the past year, with shares down 47.38%. According to InvestingPro analysis, the stock appears undervalued at current levels, with technical indicators suggesting oversold conditions. This latest price level underscores the challenges Teladoc faces in a post-pandemic market, where competition is fierce and the initial surge in telemedicine appears to be normalizing. Despite maintaining a healthy gross margin of 70.76%, investors are closely monitoring the company’s strategy to navigate through these headwinds and recapture growth momentum. Discover 10 more exclusive insights about Teladoc with InvestingPro’s comprehensive research report.
In other recent news, Teladoc Health Inc. reported its fourth-quarter 2024 earnings, revealing a revenue of $640.5 million, which slightly exceeded forecasts but was accompanied by an earnings per share (EPS) of -0.28, missing the expected -0.23. The company’s full-year revenue for 2024 was $2.6 billion, marking a 1% decrease from the previous year. Teladoc ended the year with $1.3 billion in cash and cash equivalents. Meanwhile, Teladoc has entered a partnership with Gifthealth, Eli Lilly (NYSE:LLY)’s LillyDirect pharmacy partner, to enhance access to the medication Zepbound for its Comprehensive Weight Care Program. This collaboration is aimed at providing a more streamlined and affordable option for Teladoc members without insurance coverage for GLP-1s for obesity. Analysts from Truist and Stifel maintained Hold ratings on Teladoc shares, with price targets of $10 and $9, respectively, reflecting a steady outlook despite the mixed earnings results. Needham also maintained a Hold rating, citing uncertainties in Teladoc’s growth trajectory and profitability.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.